Genentech (DNA, $98.53, up $0.68) will not win an academy award for its efforts in “evaluating” take-over offers but give the company credit for at least trying. The “special committee” that has been evaluating the $44 billion bid from Roche said this morning that the deal “substantially undervalues” the company and has been rejected.
This was no surprise as Genentech went on to say it “would consider a proposal that recognizes the value of the company and reflects the significant benefits that would accrue to Roche as a result of full ownership.” The language Genentech is using is sounding like a friendly deal could happen but it’s clear the company is holding out for a $100+ offer.
The August 95 calls (DWNHS, $3.60, up $0.85) continue to do well from an entry price of $1.50 and I mentioned you could ride them through Friday. However, we had set a stop of $3.00 so we were taken out yesterday. The August options expire Friday so make sure if you are still in the trade to close it before the trading session ends.
The September 100 calls (DWNIT, $2.95, up $0.45) were profiled at $0.65 and we have set a stop of $2.00-$2.25. The options closed at $2.50 yesterday so let’s make the $2.25 stop a firm one. I want to allow some room for volatility but I really don’t want the stop to kick in on this one. Genentech continues to set new highs and we want to ride the wave as long as we can.
Meanwhile, we closed half of the ImClone (IMCL, $64.00, down $0.51) August 45 calls (QCIHI, $19.50, down $0.15) at $19.00 on 8/1 and set a stop of $18.00 on the rest. These calls were profiled at $2.40 and our return is something even Michael Phelps would envy. These options also expire this Friday so we will go ahead and just close this one out today.
I believe both firms will get higher offers but as always it depends on timing. If Genentech continues higher from here, the September 100 calls should continue to do well. As for ImClone, I’m not sure if there is another good trade out there for us or not. I’ll take a look at the option chains and run some figures but for now we will just go with Genentech.
Rick Rouse
Rick@OptionsMentoring.com












Biotech Sector Mixed
Friday, August 1st, 2008
The biotech stocks were hot on Thursday but some of them are taking huge blows today after a drug safety scare. Elan (ELN, $11.27, down $8.78) is down another 45% following Wednesday’s 14 point drop. The stock was at $34 on Tuesday when Elan released results of a clinical trial that failed to show an overall benefit for Alzheimer’s patients who received the drug, bapineuzumab.
Biogen Idec (BIIB, $51.40, down $18.36) is also down today as it has a partnership with Elan. However, the stock is not down because of bapineuzumab. It’s the drug Tysabri that is bring down Biogen Idec. Late last night, Biogen reported that it had received word two more cases of PML, an extremely rare but potentially-deadly condition, had been confirmed in Tysabri users in Europe. Tysabri is used to treat multiple sclerosis.
The news will almost certainly make the Biogen Idec August 70 calls (IHDHN, $0.05, down $2.10) expire worthless. That’s the impact that negative news can do to option positions. We had profiled these calls at $2.30 and were out at $2.50. The update I gave Wednesday talked about setting a $2.50 stop on the calls which was hit before this news came out. Yes, we were lucky but once we had a small gain the stop was set and we took all of the emotion out of the trade.
Amylin Pharmaceuticals (AMLN, $30.20, down $1.35) is also trading lower in sympathy and the August 30 calls (AQMHF, $1.70, down $0.80) should have also been sold yesterday. They were profiled at $1.35 and are still showing a profit but I wouldn’t risk losing further profits from here with the weekend coming up.
The good news today is that ImClone Systems (IMCL, $64.45, up $0.52) is up. The August 45 calls (QCIHI, $19.20, up $0.70) are still going strong from our entry price of $2.40. Let’s go ahead and sell half of the position today and let the rest ride over the weekend. The biotech sector is always full of surprises and I don’t profile many trades in the area. However, the four I talked about Sunday have run their course and the only one that should still be open is the ImClone trade.
Rick Rouse
Rick@OptionsMentoring.com
Tags: Biotech Sector, Elan, Imclone
Posted in Company Commentary | No Comments »